A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study of the Safety and Efficacy of LY2624803 in Outpatients With Insomnia.
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2012
At a glance
- Drugs LY 2624803 (Primary) ; Zolpidem
- Indications Insomnia
- Focus Therapeutic Use
- Acronyms SLUMBER
- Sponsors Eli Lilly
- 30 Jan 2012 Actual patient numbers amended from 676 to 643 as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Feb 2010 Planned end date changed from 1 Jul 2010 to 1 Feb 2010 as reported by ClinicalTrials.gov.